Efficacy of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on proteinuria and weight in a diabetes cohort

Table 3 Glucose, renal function and body weight changes after 6 months of treatment in the glucagon like peptide-1 receptor agonist and control groups, n (%)

Variables	GLP-1RA group (n = 139)	Control group (n = 278)	P value
FBG (mmol/L)	7.91 ± 1.68	8.03 ± 2.10	0.924
Variation of FBG (mmol/L)	0.12 (-1.00, 0.97)	0.10 (-0.66, 0.58)	0.857
2hPBG (mmol/L)	9.13 ± 1.92	8.75 ± 2.29	0.274
Variation of 2hPBG (mmol/L)	0.81 (-0.65, 1.58)	-0.25 (-1.00, 0.85)	0.053
HbA1c (%)	6.73 ± 1.09	7.03 ± 1.78	0.367
Variation of HbA1c (%)	-0.09 ± 0.76	0.18 ± 1.63	0.120
UACR (mg/g)	73.60 ± 217.18	143.57 ± 513.87	0.331
Variation of UACR (mg/g)	-2.20 ± 54.36	30.16 ± 277.64	0.812
Logarithm of the variation of UACR	-0.08 ± 0.84	0.18 ± 0.94	0.416
eGFR (mL/min/1.73 m2)	83.63 ± 23.84	86.41 ± 22.56	0.659
Variation of eGFR (mL/min/1.73 m2)	-0.77 ± 10.50	0.00 ± 11.76	0.637
Body weight (kg)	77.94 ± 12.64	71.28 ± 13.80	< 0.001
Variation of body weight (kg)	-0.90 ± 3.30	0.27 ± 3.55	< 0.001
BMI (kg/m2)	27.64 ± 4.06	25.02 ± 3.70	< 0.001
Variation of BMI (kg/m2)	-0.33 ± 1.17	0.08 ± 1.26	0.001
UACR grades
< 30 mg/g	47 (72.31)	82 (78.85)	0.273
30-300 mg/g	4 (6.15)	10 (9.62)
> 300 mg/g	14 (21.54)	12 (11.54)
Renal composite outcome	0 (0.00)	2 (0.72)	0.637
BMI grades
18-24 kg/m2	0 (0.00)	4 (2.19)	< 0.001
24-28 kg/m2	16 (14.29)	67 (36.61)
28-35 kg/m2	52 (46.43)	73 (39.89)
> 35 kg/m2	44 (39.29)	39 (21.31)

FBG: Fasting blood glucose; PBG: Prandial blood glucose; HbA_1c: Glycosylated hemoglobin; UACR: Urinary albumin-creatinine ratio; eGFR: Estimated glomerular filtration rate; BMI: Body mass index; GLP-1RA: Glucagon like peptide-1 receptor agonist.